Roche’s efforts to break into the lucrative obesity market haven’t abated. The pharma giant sealed the largest deal in the space earlier this year when it announced a collaboration with Zealand Pharma ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

The latest round of terminations, which will take effect Sept. 15, comes after Genentech fired more than 500 employees in the ...

Investing.com -- Wells Fargo (NYSE: WFC) has initiated coverage of Zealand Pharma (NASDAQ: ZEAL) with an Overweight rating ...

Dealmaking in Europe’s life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Analyst activity included BNP Paribas (OTC: BNPQY) Exane initiating coverage on Zealand Pharma with an Outperform rating, suggesting a potential upside based on its valuation model. Meanwhile, Cantor ...

Forward-Looking Statements Zealand has made significant progress against its 2024 priorities, particularly with the Petrelintide Phase 1b data and the Survodutide Phase 2 MASH trial results. The ...